{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:46:34Z","timestamp":1790142394410,"version":"4.0.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s15010-021-01735-1","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T06:33:37Z","timestamp":1638426817000},"page":"467-474","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Epidemiology and in vitro activity of ceftazidime\u2013avibactam, meropenem\u2013vaborbactam, imipenem\u2013relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0945-1732","authenticated-orcid":false,"given":"Sofia","family":"Maraki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria Eirini","family":"Mavromanolaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Magkafouraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Moraitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Stafylaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kasimati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Effie","family":"Scoulica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,2]]},"reference":[{"key":"1735_CR1","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S1473-3099(09)70054-4","volume":"9","author":"P Nordmann","year":"2009","unstructured":"Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009;9:228\u201336.","journal-title":"Lancet Infect Dis"},{"key":"1735_CR2","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.3201\/eid2007.121004","volume":"2","author":"ME Falagas","year":"2014","unstructured":"Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas KZ. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis. 2014;2:1170\u20135.","journal-title":"Emerg Infect Dis"},{"key":"1735_CR3","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1093\/infdis\/jiw282","volume":"215","author":"LK Logan","year":"2017","unstructured":"Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis. 2017;215:S28\u201336.","journal-title":"J Infect Dis"},{"key":"1735_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40121-020-00395-2","volume":"10","author":"GT Hansen","year":"2021","unstructured":"Hansen GT. Continuous evolution: perspective on the epidemiology of carbapenemase resistance among Enterobacterales and Other Gram-Negative Bacteria. Infect Dis Ther. 2021;10:75\u201392.","journal-title":"Infect Dis Ther"},{"key":"1735_CR5","unstructured":"Centers for Disease Control and Prevention (CDC) (2019) Antimicrobial resistance threats report. Available from: https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/2019-ar-threats-report-508.pdf. Accessed 5 Jan 2021"},{"key":"1735_CR6","unstructured":"World Health Organization (WHO) (2017) Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. Available from: http:\/\/www.who.int\/medicines\/publications\/WHO-PPL-ShortSummary_25Feb-ET_NM_WHO.pdf. Accessed 12 Dec 2020"},{"key":"1735_CR7","unstructured":"European Centre for Disease Prevention and Control (2019) Surveillance of antimicrobial resistance in Europe-annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) 2019. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/surveillance-antimicrobial-resistance-europe-2019.pdf. Accessed 20 Jan 2021"},{"key":"1735_CR8","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S1473-3099(19)30755-8","volume":"20","author":"D van Duin","year":"2020","unstructured":"van Duin D, Arias CA, Komarow L, Chen L, Hanson BM, Weston G, et al. Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study. Lancet Infect Dis. 2020;20:731\u201341.","journal-title":"Lancet Infect Dis"},{"key":"1735_CR9","doi-asserted-by":"publisher","first-page":"e0200020","DOI":"10.1128\/AAC.02000-20","volume":"65","author":"KM Kazmierczak","year":"2021","unstructured":"Kazmierczak KM, Karlowsky JA, de Jonge BLM, Stone GG, Sahm DF. Epidemiology of carbapenem resistance determinants identified in meropenem-nonsusceptible Enterobacterales collected as part of a global surveillance program, 2012 to 2017. Antimicrob Agents Chemother. 2021;65:e0200020.","journal-title":"Antimicrob Agents Chemother"},{"key":"1735_CR10","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1080\/14656566.2020.1779221","volume":"21","author":"M Spaziante","year":"2020","unstructured":"Spaziante M, Oliva A, Ceccarelli G, Venditti M. What are the treatment options for resistant Klebsiella pneumoniae carbapenemase (KPC)-producing bacteria? Expert Opin Pharmacother. 2020;21:1781\u20137.","journal-title":"Expert Opin Pharmacother"},{"key":"1735_CR11","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1128\/AAC.02166-13","volume":"58","author":"GL Daikos","year":"2014","unstructured":"Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58:2322\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"1735_CR12","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/jac\/dkq210","volume":"65","author":"A Tsakris","year":"2010","unstructured":"Tsakris A, Poulou A, Pournaras S, Voulgari E, Vrioni G, Themeli-Digalaki K, et al. A simple phenotypic method for the differentiation of metallo-beta-lactamases and class A KPC carbapenemases in Enterobacteriaceae clinical isolates. J Antimicrob Chemother. 2010;65:1664\u201371.","journal-title":"J Antimicrob Chemother"},{"key":"1735_CR13","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1128\/JCM.03361-13","volume":"52","author":"A Poulou","year":"2014","unstructured":"Poulou A, Grivakou E, Vrioni G, Koumaki V, Pittaras T, Pournaras S, et al. Modified CLSI extended-spectrum \u03b2-lactamase (ESBL) confirmatory test for phenotypic detection of ESBLs among Enterobacteriaceae producing various \u03b2-lactamases. J Clin Microbiol. 2014;52:1483\u20139.","journal-title":"J Clin Microbiol"},{"key":"1735_CR14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.diagmicrobio.2010.12.002","volume":"70","author":"L Poirel","year":"2011","unstructured":"Poirel L, Walsh TR, Cuvillier V, Nordmann P. Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis. 2011;70:119\u201323.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1735_CR15","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1128\/JCM.43.8.4178-4182.2005","volume":"43","author":"L Diancourt","year":"2005","unstructured":"Diancourt L, Passet V, Verhoef J, Grimont PA, Brisse S. Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates. J Clin Microbiol. 2005;43:4178\u201382.","journal-title":"J Clin Microbiol"},{"key":"1735_CR16","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation for MICs and zone diameters: version 10.0, valid from 2020\u201301\u201301. EUCAST, Basel, Switzerland; 2020."},{"key":"1735_CR17","unstructured":"Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; 30th ed. (M100-S30); 2020."},{"key":"1735_CR18","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268\u201381.","journal-title":"Clin Microbiol Infect"},{"key":"1735_CR19","doi-asserted-by":"publisher","first-page":"3893","DOI":"10.1128\/JCM.41.8.3893-3896.2003","volume":"41","author":"P Giakkoupi","year":"2003","unstructured":"Giakkoupi P, Xanthaki A, Kanelopoulou M, Vlahaki A, Miriagou V, Kontou S, et al. VIM-1 Metallo-beta-lactamase-producing Klebsiella pneumoniae strains in Greek hospitals. J Clin Microbiol. 2003;41:3893\u20136.","journal-title":"J Clin Microbiol"},{"key":"1735_CR20","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jinf.2009.01.010","volume":"58","author":"HC Maltezou","year":"2009","unstructured":"Maltezou HC, Giakkoupi P, Maragos A, Bolikas M, Raftopoulos V, Papahatzaki H, et al. Outbreak of infections due to KPC-2-producing Klebsiella pneumoniae in a hospital in Crete (Greece). J Infect. 2009;58:213\u20139.","journal-title":"J Infect"},{"key":"1735_CR21","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2018.23.30.1700775","author":"I Galani","year":"2018","unstructured":"Galani I, Karaiskos I, Karantani I, Papoutsaki V, Maraki S, Papaioannou V, et al. Epidemiology and resistance phenotypes of carbapenemase-producing Klebsiella pneumoniae in Greece, 2014 to 2016. Euro Surveill. 2018. https:\/\/doi.org\/10.2807\/1560-7917.ES.2018.23.30.1700775.","journal-title":"Euro Surveill"},{"key":"1735_CR22","doi-asserted-by":"publisher","first-page":"809","DOI":"10.2217\/fmb-2016-0042","volume":"11","author":"T Karampatakis","year":"2016","unstructured":"Karampatakis T, Antachopoulos C, Iosifidis E, Tsakris A, Roilides E. Molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae in Greece. Future Microbiol. 2016;11:809\u201323.","journal-title":"Future Microbiol"},{"key":"1735_CR23","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1089\/mdr.2018.0327","volume":"25","author":"A Piazza","year":"2019","unstructured":"Piazza A, Comandatore F, Romeri F, Brilli M, Dichirico B, Ridolfo A, et al. Identification of blaVIM-1 gene in ST307 and ST661 Klebsiella pneumoniae clones in Italy: old acquaintances for new combinations. Microb Drug Resist. 2019;25:787\u201390.","journal-title":"Microb Drug Resist"},{"key":"1735_CR24","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1093\/jac\/dkr166","volume":"66","author":"P Giakkoupi","year":"2011","unstructured":"Giakkoupi P, Papagiannitsis CC, Miriagou V, Pappa O, Polemis M, Tryfinopoulou K, et al. An update of the evolving epidemic of blaKPC-2-carrying Klebsiella pneumoniae in Greece (2009\u201310). J Antimicrob Chemother. 2011;66:1510\u20133.","journal-title":"J Antimicrob Chemother"},{"key":"1735_CR25","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1179\/1973947813Y.0000000075","volume":"25","author":"CC Papagiannitsis","year":"2013","unstructured":"Papagiannitsis CC, Giakkoupi P, Kotsakis SD, Tzelepi E, Tzouvelekis LS, Vatopoulos AC, et al. OmpK35 and OmpK36 porin variants associated with specific sequence types of Klebsiella pneumoniae. J Chemother. 2013;25:250\u20134.","journal-title":"J Chemother"},{"key":"1735_CR26","doi-asserted-by":"publisher","first-page":"e02457","DOI":"10.1128\/AAC.02457-17","volume":"62","author":"K Avgoulea","year":"2018","unstructured":"Avgoulea K, Di Pilato V, Zarkotou O, Sennati S, Politi L, Cannatelli A, et al. Characterization of extensively drug-resistant or pandrug-resistant Sequence Type 147 and 101 OXA-48-producing Klebsiella pneumoniae causing bloodstream infections in patients in an intensive care unit. Antimicrob Agents Chemother. 2018;62:e02457-e2517.","journal-title":"Antimicrob Agents Chemother"},{"key":"1735_CR27","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1128\/AAC.03042-15","volume":"60","author":"BL de Jonge","year":"2016","unstructured":"de Jonge BL, Karlowsky JA, Kazmierczak KM, Biedenbach DJ, Sahm DF, Nichols WW. In vitro susceptibility to ceftazidime\u2013avibactam of carbapenem-nonsusceptible Enterobacteriaceae isolates collected during the INFORM global surveillance study (2012 to 2014). Antimicrob Agents Chemother. 2016;60:3163\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"1735_CR28","doi-asserted-by":"publisher","first-page":"106111","DOI":"10.1016\/j.ijantimicag.2020.106111","volume":"56","author":"GM Rossolini","year":"2020","unstructured":"Rossolini GM, Stone GG. Assessment of the in vitro activity of ceftazidime\/avibactam against a global collection of multidrug-resistant Klebsiella spp. from the INFORM surveillance programme (2015\u20132017). Int J Antimicrob Agents. 2020;56:106111.","journal-title":"Int J Antimicrob Agents"},{"key":"1735_CR29","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1093\/jac\/dkz456","volume":"75","author":"I Spiliopoulou","year":"2020","unstructured":"Spiliopoulou I, Kazmierczak K, Stone GG. In vitro activity of ceftazidime\/avibactam against isolates of carbapenem-non-susceptible Enterobacteriaceae collected during the INFORM global surveillance programme (2015\u201317). J Antimicrob Chemother. 2020;75:384\u201391.","journal-title":"J Antimicrob Chemother"},{"key":"1735_CR30","doi-asserted-by":"publisher","first-page":"e00567","DOI":"10.1128\/AAC.00567-17","volume":"61","author":"M Castanheira","year":"2017","unstructured":"Castanheira M, Huband MD, Mendes RE, Flamm RK. Meropenem-vaborbactam tested against contemporary Gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2017;61:e00567-e617.","journal-title":"Antimicrob Agents Chemother"},{"key":"1735_CR31","first-page":"e01904","volume":"62","author":"MA Hackel","year":"2017","unstructured":"Hackel MA, Lomovskaya O, Dudley MN, Karlowsky JA, Sahm DF. In vitro activity of meropenem\u2013vaborbactam against clinical isolates of KPC-positive Enterobacteriaceae. Antimicrob Agents Chemother. 2017;62:e01904-e1917.","journal-title":"Antimicrob Agents Chemother"},{"key":"1735_CR32","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ijantimicag.2018.02.021","volume":"52","author":"MA Pfaller","year":"2018","unstructured":"Pfaller MA, Huband MD, Mendes RE, Flamm RK, Castanheira M. In vitro activity of meropenem\/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem\/ vaborbactam surveillance programme. Int J Antimicrob Agents. 2018;52:144\u201350.","journal-title":"Int J Antimicrob Agents"},{"key":"1735_CR33","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s10096-019-03517-y","volume":"38","author":"I Galani","year":"2019","unstructured":"Galani I, Souli M, Nafplioti K, Adamou P, Karaiskos I, Giamarellou H, et al. In vitro activity of imipenem\u2013relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015\u20132016. Eur J Clin Microbiol Infect Dis. 2019;38:1143\u201350.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1735_CR34","doi-asserted-by":"publisher","first-page":"S427","DOI":"10.1093\/cid\/ciaa1519","volume":"71","author":"Q Yang","year":"2020","unstructured":"Yang Q, Zhang H, Yu Y, Kong H, Duan Q, Wang Y, et al. In vitro activity of imipenem\/relebactam against Enterobacteriaceae isolates obtained from intra-abdominal, respiratory tract, and urinary tract infections in China: Study for Monitoring Antimicrobial Resistance Trends (SMART), 2015\u20132018. Clin Infect Dis. 2020;71:S427\u201335.","journal-title":"Clin Infect Dis"},{"key":"1735_CR35","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1093\/jpids\/piaa056","volume":"10","author":"JA Karlowsky","year":"2021","unstructured":"Karlowsky JA, Lob SH, Young K, Motyl MR, Sahm DF. In vitro activity of imipenem\/relebactam against Gram-negative bacilli from pediatric patients-Study for Monitoring Antimicrobial Resistance Trends (SMART) global surveillance program 2015\u20132017. J Pediatric Infect Dis Soc. 2021;10:274\u201381.","journal-title":"J Pediatric Infect Dis Soc"},{"key":"1735_CR36","doi-asserted-by":"publisher","first-page":"115421","DOI":"10.1016\/j.diagmicrobio.2021.115421","volume":"100","author":"SH Lob","year":"2021","unstructured":"Lob SH, Hackel MA, Young K, Motyl MR, Sahm DF. Activity of imipenem\/ relebactam and comparators against gram-negative pathogens from patients with bloodstream infections in the United States and Canada\u2014SMART 2018\u20132019. Diagn Microbiol Infect Dis. 2021;100:115421.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1735_CR37","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/ja.2016.73","volume":"69","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Lin X, Bush K. In vitro susceptibility of \u03b2-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline. J Antibiot. 2016;69:600\u20134.","journal-title":"J Antibiot"},{"key":"1735_CR38","doi-asserted-by":"publisher","first-page":"3840","DOI":"10.1128\/AAC.00436-16","volume":"60","author":"DM Livermore","year":"2016","unstructured":"Livermore DM, Mushtaq S, Warner M, Woodford N. In vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii. Antimicrob Agents Chemother. 2016;60:3840\u20134.","journal-title":"Antimicrob Agents Chemother"},{"key":"1735_CR39","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12879-019-3801-1","volume":"19","author":"I Galani","year":"2019","unstructured":"Galani I, Nafplioti K, Adamou P, Karaiskos I, Giamarellou H, Souli M, et al. Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance. BMC Infect Dis. 2019;19:167.","journal-title":"BMC Infect Dis"},{"key":"1735_CR40","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.diagmicrobio.2017.11.004","volume":"90","author":"AF Martins","year":"2018","unstructured":"Martins AF, Bail L, Ito CAS, da Silva NK, Dalmolin TV, Martins AS, et al. Antimicrobial activity of plazomicin against Enterobacteriaceae-producing carbapenemases from 50 Brazilian medical centers. Diagn Microbiol Infect Dis. 2018;90:228\u201332.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1735_CR41","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/jac\/dkq408","volume":"66","author":"DM Livermore","year":"2011","unstructured":"Livermore DM, Mushtaq S, Warner M, Zhang JC, Maharjan S, Doumith M, et al. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother. 2011;66:48\u201353.","journal-title":"J Antimicrob Chemother"},{"key":"1735_CR42","doi-asserted-by":"publisher","first-page":"e02418","DOI":"10.1128\/AAC.02418-19","volume":"64","author":"M Castanheira","year":"2020","unstructured":"Castanheira M, Sader HS, Mendes RE, Jones RN. Activity of plazomicin tested against Enterobacterales isolates collected from U.S. Hospitals in 2016\u20132017: effect of different breakpoint criteria on susceptibility rates among aminoglycosides. Antimicrob Agents Chemother. 2020;64:e02418\u20139.","journal-title":"Antimicrob Agents Chemother"}],"updated-by":[{"DOI":"10.1007\/s15010-022-01918-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000}}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-021-01735-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-021-01735-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-021-01735-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T06:21:42Z","timestamp":1665123702000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-021-01735-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,2]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1735"],"URL":"https:\/\/doi.org\/10.1007\/s15010-021-01735-1","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s15010-022-01918-4","asserted-by":"object"}]},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,2]]},"assertion":[{"value":"14 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s15010-022-01918-4","URL":"https:\/\/doi.org\/10.1007\/s15010-022-01918-4","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethical Committee of the University Hospital of Heraklion and met the guidelines of Helsinki declarations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}